Filtered By:
Condition: Heart Attack
Drug: Metformin
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 151 results found since Jan 2013.
Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second ‐ and third‐line antidiabetic drugs in patients with type 2 diabetes
ConclusionsDPP4is as a second‐ or third‐line add‐on treatment provided cardiovascular benefits and posed no increased risks for heart failure, hypoglycaemia or death.
Source: British Journal of Clinical Pharmacology - February 26, 2017 Category: Drugs & Pharmacology Authors: Huang ‐Tz Ou, Kai‐Cheng Chang, Chung‐Yi Li, Jin‐Shang Wu Tags: DRUG SAFETY Source Type: research
Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care ‐based cohort study, with economic assessment of patient outcomes
ConclusionsWith respect to treatment choice, data from the present study support the notion of prescribing beyond metformin + SU, as alternative regimens have been shown to be associated with reduced outcomes risk and value for money.
Source: Diabetes, Obesity and Metabolism - February 22, 2017 Category: Endocrinology Authors: Jason Gordon, Phil McEwan, Marc Evans, Jorge Puelles, Alan Sinclair Tags: ORIGINAL ARTICLE Source Type: research
Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs.
Abstract
PURPOSE: We performed a systematic review of patient-centered outcomes after the concomitant use of proton pump inhibitors (PPIs) and other drugs.
METHODS: We searched 4 databases in July 2016 to find studies that reported mortality and morbidity after the concomitant use of PPIs and other drugs. We conducted direct meta-analyses using a random-effects model and graded the quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation working group approach.
FINDINGS: We included data from 17 systematic reviews and meta-analyses, 16 randomized controlled t...
Source: Clinical Therapeutics - February 8, 2017 Category: Drugs & Pharmacology Authors: Shamliyan TA, Middleton M, Borst C Tags: Clin Ther Source Type: research
Comparative cardiovascular risks of dipeptidyl peptidase ‐4 inhibitors with other 2nd and 3rd line antidiabetic drugs in patients with type 2 diabetes
ConclusionsDPP4i as 2nd and 3rd add‐on treatment provided cardiovascular benefits and posed no increased risks for heart failure, hypoglycemia and death.
Source: British Journal of Clinical Pharmacology - January 21, 2017 Category: Drugs & Pharmacology Authors: Huang ‐Tz Ou, Kai‐Cheng Chang, Chung‐Yi Li, Jin‐Shang Wu Tags: DRUG SAFETY Source Type: research
Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
This article reviews evidence of benefits and risk of antidiabetic agents in cardiovascular (CV) outcomes, with a focus on medications approved by the FDA since 2008. Peer-reviewed articles were identified from MEDLINE and Current Content database (both 1966 to October 1, 2016) using the search terms insulin, metformin, rosiglitazone, pioglitazone, glyburide, glipizide, glimepiride, acarbose, miglitol, albiglutide, exenatide, liraglutide, lixisenatide, dulaglutide, pramlintide, meglitinide, alogliptin, linagliptin, saxagliptin, sitagliptin, canagliflozin, dapagliflozin, empagliflozin, colesevalam, bromocriptine, mortality,...
Source: Current Medical Research and Opinion - January 19, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care based cohort study, with economic assessment of patient outcomes
ConclusionsWith respect to treatment choice, data from this study supports the notion of prescribing beyond M+SU, as alternative regimens have been demonstrated to be associated with reduced outcomes risk and value for money.
Source: Diabetes, Obesity and Metabolism - December 26, 2016 Category: Endocrinology Authors: Jason Gordon, Phil McEwan, Marc Evans, Jorge Puelles, Alan Sinclair Tags: ORIGINAL ARTICLE Source Type: research
Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study
This study provides reassurance of the overall safety of insulin use in the treatment of type 2 diabetes and contributes to our understanding of the contrasting conclusions from non-randomised and randomised studies regarding dose-dependent effects of insulin on cardiovascular events and mortality. Funding Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, and the Newfoundland and Labrador Research and Development Corporation.
Source: The Lancet Diabetes and Endocrinology - November 16, 2016 Category: Endocrinology Source Type: research
Cardiovascular Effects of Glucose-Lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
Abstract
PURPOSE: The purpose of this study was to review the results of clinical trials assessing the cardiovascular effects of drugs for type 2 diabetes and the cardiovascular effects of newer available drugs.
METHODS: We performed a detailed search of PubMed-listed publications, reports from international meetings, and ongoing studies from clinical trials.gov.
FINDINGS: Currently available drugs have neutral or, in some cases, negative effects on cardiovascular outcomes. Modern sulfonylureas appear to be safe, although the biguanide metformin has a slightly better cardiovascular safety profile than th...
Source: Clinical Therapeutics - November 14, 2016 Category: Drugs & Pharmacology Authors: Thompson PL, Davis TM Tags: Clin Ther Source Type: research
Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
CONCLUSION: These findings suggest that in T2DM subjects on metformin, BQR therapy may represent an effective strategy for reducing CVD risk.
PMID: 27687032 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - October 2, 2016 Category: Internal Medicine Tags: Postgrad Med Source Type: research
Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes
Conclusions
In this cohort of obese people with T2DM, intensification of dual oral therapy by adding GLP-1ar analogue is associated with a lower MACE outcome in routine clinical practice, compared with adding insulin therapy as the third glucose-lowering agent.
Source: Heart - September 12, 2016 Category: Cardiology Authors: Anyanwagu, U., Mamza, J., Mehta, R., Donnelly, R., Idris, I. Tags: Drugs: cardiovascular system, Acute coronary syndromes, Epidemiology, Diabetes, Metabolic disorders Healthcare delivery, economics and global health Source Type: research
Intensive treatment of type 2 diabetes with microalbuminuria reaps benefits
Patients live longer, and with fewer complications, than those treated conventionally Related items fromOnMedica Metformin lowers cardiac deaths better than other drugs NHS Health Check waste of time and money, says study Diabetes, stroke and heart attack cut life expectancy Send children with suspected diabetes to hospital immediately, GPs urged NHS must hold CCGs accountable for poor diabetes care
Source: OnMedica Latest News - September 1, 2016 Category: UK Health Source Type: news
Comparative risk of major cardiovascular events associated with second ‐line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records
ConclusionsThiazolidinedione add‐on treatments to metformin were associated with lower risks of major cardiovascular disease or cardiovascular death compared with sulphonylurea add‐on treatment to metformin. Lower, but non‐statistically significant, risks were also found with DPP‐4 inhibitor add‐on therapies.
Source: Diabetes, Obesity and Metabolism - June 29, 2016 Category: Endocrinology Authors: S. S. Zghebi, D. T. Steinke, M. K. Rutter, R. A. Emsley, D. M. Ashcroft Tags: ORIGINAL ARTICLE Source Type: research
Identifying the independent effect of HbA1c variability on adverse health outcomes in patients with Type 2 diabetes
ConclusionsIn veterans with Type 2 diabetes, greater HbA1c variability was associated with an increased risk of adverse long‐term outcomes, independently of HbA1c levels and direction of change. Limiting HbA1c fluctuations over time may reduce complications.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - June 8, 2016 Category: Endocrinology Authors: J. C. Prentice, S. D. Pizer, P. R. Conlin Tags: Research Article Source Type: research
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Abstract
During the last decade, the armamentarium for glucose-lowering drugs has increased enormously by the development of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors, allowing individualization of antidiabetic therapy for patients with type 2 diabetes (T2DM). Some combinations can now be used without an increased risk for severe hypoglycemia and weight gain. Following a request of the US Food and Drug Administration, many large cardiovascular (CV) outcome studies have been performed in patients with longstanding disease and established CV disease. In the majority of CV outcome studies, CV ris...
Source: Clinical Therapeutics - May 18, 2016 Category: Drugs & Pharmacology Authors: Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH Tags: Clin Ther Source Type: research
Comparative Risk for Cardiovascular Diseases of Dipeptidyl Peptidase-4 Inhibitors vs. Sulfonylureas in Combination with Metformin: Results of a Two-Phase Study
The aim was to assess whether the use of additional data from the Disease Management Program (DMP) diabetes mellitus type 2 to minimize the potential for residual confounding will alter the estimated risk of either myocardial infarction, ischemic stroke or heart failure in patients with type 2 diabetes using sulfonylureas compared to dipeptidyl peptidase-4 (DPP-4) inhibitors in addition to metformin based on routine health care data.
Source: Journal of Diabetes and Its Complications - May 18, 2016 Category: Endocrinology Authors: Dirk Enders, Bianca Kollhorst, Susanne Engel, Roland Linder, Frank Verheyen, Iris Pigeot Source Type: research
